Background-Studies examining the association between radial approach and post-percutaneous coronary intervention (PCI) bleeding and mortality have reached conflicting conclusions. There are no current data about the use and outcomes of transradial PCI (r-PCI) in the Veterans Affairs system.
P eriprocedural bleeding and vascular complications in patients undergoing percutaneous coronary intervention (PCI) are common and associated with increased morbidity and mortality. Major bleeding is reported to occur in 5% to 10% of patients undergoing PCI in the setting of acute coronary syndromes and often occurs at the vascular access site. 1, 2 In some studies, the radial approach to PCI (r-PCI) is associated with decreased post-PCI bleeding and blood transfusion, whereas in others, the benefits of radial access were limited to reduced vascular complications and not bleeding. [3] [4] [5] [6] Moreover, studies have not consistently shown an association between radial approach and decreased mortality across the spectrum of patients undergoing PCI. Because of this inconsistency, the use of the radial approach to decrease vascular complications is given a class IIA recommendation by current treatment guidelines, and there is limited uptake of the radial approach worldwide, especially in the United States. [7] [8] [9] [10] Interestingly, the advantages of transradial over transfemoral PCI (f-PCI) seem to be greater among centers routinely performing radial procedures. 4 If the relationship between r-PCI and reduced PCI complications is confirmed, then it could have greater impact in closed healthcare systems such as the Veterans Affairs (VA) healthcare system. The VA provides care to 8.3 million veterans annually and is the largest publicly funded hospital system in the United States; ≈500 000 veterans have a diagnosis of ischemic heart disease, and it is the leading cause of mortality and hospitalization for veterans. 11, 12 Mortality rates for veterans with ischemic heart disease have declined over time and have paralleled those seen among Medicare beneficiaries. 13 This has been attributed to the combination of steady advances in ischemic heart disease care and aggressive quality improvement efforts within the VA, including the implementation of VA-wide quality improvement registries for patients with ischemic heart disease and those undergoing cardiac catheterization and PCI. The use of r-PCI and associated outcomes in the VA has not been examined previously. Accordingly, we used data from the VA's cooperative, nationwide centralized catheterization laboratory registry to determine the prevalence and outcomes of r-PCI compared with f-PCI. We hypothesized that the adoption of r-PCI within the VA increased over time, and that the radial approach was associated with improved PCI outcomes, especially among VA hospitals that had higher radial volumes.
Methods

Study Sample
Launched in 2005, the Clinical Assessment, Reporting, and Tracking (CART) Program is a national VA clinical quality initiative. The program has 3 missions: to support clinical care, to promote the quality of care, and to advance knowledge through research. The program's initial focus is on procedures performed in any of the 78 VA cardiac catheterization laboratories nationwide.
A key feature of the CART Program is a clinical software application designed to collect data on catheterization laboratory procedures in a standardized fashion. The software is embedded in the VA electronic health record and allows providers to enter patient and procedural information (preprocedure assessment, cardiac catheterization, and PCI) as part of routine clinical workflow. Once data entry is complete, the data elements automatically populate a clinical note for the patient electronic health record. These data are combined with longitudinal VA administrative data in a clinical data repository to support the quality assessment, quality improvement, and clinical research missions of the CART Program.
The CART Program is designed using standardized definitions and features, such as pull-down menus, to ensure a uniformity of data entry by different providers and in different catheterization laboratories. Core data elements recorded by CART Program conform to the definitions and standards of the American College of Cardiology's National Cardiovascular Data Registry (ACC-NCDR). 14, 15 Quality checks of the CART Program data are periodically performed for completeness and accuracy.
This study uses data for the first PCI procedure of any individual undergoing PCI in the VA between October 1, 2007, and September 30, 2010 (n=24 983 at 60 hospitals). PCI procedures that were missing access site information (n=780) or involving an access site other than radial or femoral artery (n=60) were excluded. For the analyses, another 2685 PCIs were excluded because they were at sites that did not perform any r-PCIs during the study period (n=11 sites). The cohort of 21 458 PCIs at 49 sites performing ≥1 r-PCI was also stratified into low r-PCI volume sites (19 044 PCIs at 44 sites) and high r-PCI volume sites (2414 PCIs at 5 sites; Figure 1 ).
Definitions and End Points
Site of vascular access is defined as the site of successful vascular entry. The CART Program does not capture attempted unsuccessful vascular access. Procedure success is defined as residual stenosis ≤20%, or 50% decrease in stenosis severity in all lesions attempted. The primary efficacy outcome was mortality. The CART Program does not capture bleeding complications; however, transfusions are recorded in VA administrative data. Therefore, the primary safety outcome was the incidence of blood transfusions within 30 days after PCI.
Statistical Analysis
Patients were grouped according to access site used for PCIradial or femoral. Baseline characteristics, including demographics, medical comorbidities, and procedural details, were compared for r-PCI and f-PCI patients using Mann-Whitney-Wilcoxon nonparametric tests for continuous variables and Pearson χ 2 tests for categorical variables.
Because patient characteristics and comorbidities may influence the choice of access site, propensity score matching was used to create 3 cohorts balanced in demographics and comorbidities: (1) a cohort including all sites with ≥1 r-PCI performed during the study period (n=49 sites); (2) a cohort including all high r-PCI volume sites (n=5 sites); and (3) a cohort including all low r-PCI volume sites (n=44 sites). For analyses, sites performing ≥1 r-PCI were also stratified into high and low volume sites. High volume sites were defined as the sites with ≥50 r-PCIs in Fiscal Year 10, the last year of the study period. Low r-PCI volume sites were defined as all sites that did not meet the criteria for high r-PCI volume. A cutoff of 50 r-PCIs for stratifying sites for analysis as high volume was implemented because of literature support of 50 r-PCI cases being required to achieve outcomes similar to experienced radial access operators. 16 
WHAT IS KNOWN
• Procedural bleeding and vascular complications in the setting of percutaneous coronary intervention (PCI) are associated with increased morbidity and mortality.
• Radial access use for PCI is associated with reduced bleeding and vascular complications.
WHAT THE STUDY ADDS
• Current data on the use and outcomes of radial access for PCI within the Veterans Affairs Healthcare System.
• The majority of the Veterans Affairs Healthcare
System catheterization laboratories are low radial access centers for PCI.
• Within the Veterans Affairs Healthcare System, the advantage of radial access compared with femoral access for PCI in terms of reduced blood transfusion is limited to sites performing higher radial access volumes. Values represent n (%) or median (25th, 75th). ACS indicates acute coronary syndrome; CVD, cerebrovascular disease; COPD, chronic obstructive pulmonary disease; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; r-PCI, transradial PCI; and STEMI, ST-segment-elevation myocardial infarction.
Binary logistic regression was used to estimate a propensity score for undergoing r-PCI. The following variables were considered for inclusion in the propensity score model: age, sex, race, ethnicity, diabetes mellitus, dyslipidemia, hypertension, renal failure, cerebrovascular disease, peripheral vascular disease, obesity, overweight, chronic obstructive pulmonary disease, indication for PCI, smoking history, and year. We did not adjust for hospital or hospital-level r-PCI volume because these factors were highly associated with the choice of access site and less associated with outcomes and thus would likely lead to Z-bias in the propensity score estimates. 17 We did not adjust for procedural factors, such as fluoroscopy time or multivessel PCI, because these factors could be associated with both the choice of access site and the outcome.
There was adequate overlap in propensity scores for r-PCI and f-PCI cases, and records with propensity scores in the top 1% or bottom 1% were removed before matching. A 3-to-1 caliper-matching algorithm was used with a caliper of 0.1× the SD of the logit of the propensity score. [18] [19] [20] We used the SAS macro PSMatching. 16 Standardized differences before and after matching were used to evaluate the balance of covariates in the matched cohorts. An absolute difference of <10% is commonly considered adequate balance. 21 The maximum standardized difference was 7.4% for the cohort of all sites, 6.3% for the cohort of low r-PCI volume sites, and 9.5% for the cohort of high r-PCI volume sites.
Procedure success rates were compared between the access site groups in the full and matched data sets. Kaplan-Meier survival curves were used to compare overall survival and blood transfusions by PCI access site in the matched cohort. Kaplan-Meier estimates of event probabilities were also used to compare mortality at 30 and 360 days and blood transfusions at 3 and 7 days post-PCI between r-PCI and f-PCI. To evaluate the relative hazards of death and blood transfusion associated with PCI access site in the propensity-matched cohorts, we used Cox proportional hazards survival models with robust sandwich covariance matrix estimates to account for intrahospital dependence. 22 Statistical analyses were performed using SAS software (version 9.2, SAS Institute, Cary, NC). 23 All analyses were performed at the CART Coordinating Center at the Denver VA Medical Center. This study was approved by the Institutional Review Board at the Denver VA Medical Center and the Durham VA Medical Center. Values represent n (%) or median (25th, 75th). ACS indicates acute coronary syndrome; CVD, cerebrovascular disease; COPD, chronic obstructive pulmonary disease; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; r-PCI, transradial PCI; and STEMI, ST-segment-elevation myocardial infarction. Values represent n (%) or median (25th, 75th). ACS indicates acute coronary syndrome; CVD, cerebrovascular disease; COPD, chronic obstructive pulmonary disease; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; r-PCI, transradial PCI; and STEMI, ST-segment-elevation myocardial infarction.
Results
Study Sample
Of the 24 143 procedures entered into the CART Program during the study period, 22 834 (94.6%) were f-PCI and 1309 (5.4%) were r-PCI; 49 (82%) of the 60 PCI sites performed ≥1 r-PCI during the study period. Among these sites, there were 21 458 PCIs, of which 6.1% were r-PCI (Table 1) . 
Trends in r-PCI Over Time
Hospital Variation
Sites varied dramatically in terms of r-PCI volume (Figure 3 ); 20% of sites performed only 1 to 3 r-PCIs during the 3-year study period, whereas 2 sites performed >40% of total PCI procedures via the radial approach. The median total number of r-PCI procedures was 7 (interquartile range, 2-18), and the maximum was 419. Table 1 displays baseline patient characteristics of f-PCI versus r-PCI procedures in the data from all sites with ≥1 r-PCIs before and after propensity score matching. Compared with f-PCI, patients undergoing r-PCI had significantly more comorbidities, such as diabetes mellitus, dyslipidemia, hypertension, tobacco use, cerebral vascular disease, peripheral arterial disease, chronic obstructive pulmonary disease, and obesity, but most of these factors were not significantly different by PCI access site after matching. Some factors still had significant differences by access site after matching, but the standardized differences (which are a more appropriate measure of covariate balance in a propensity-matched sample) were always <10%. 24 Tables 2 and 3 display the same information for the data from the high and low r-PCI volume sites.
Patient Characteristics
Procedure Characteristics
In the data set of all sites performing r-PCIs, compared with f-PCI, patients who underwent r-PCI less often underwent procedures for acute coronary syndromes and experienced longer fluoroscopy times. There was no significant difference in multivessel PCI between the 2 groups. The use of glycoprotein IIb/IIIa inhibitors was more common in f-PCI procedures, whereas the use of bivalirudin was more common in patients undergoing r-PCI (Table 1) . After propensity matching, there was no difference in procedural success rates between f-PCI and r-PCI among sites that performed ≥1 r-PCI (f-PCI 96.6% versus r-PCI 97.3%; P=0.182), high radial volumes (f-PCI 96.1% versus r-PCI 97.2%; P=0.269), and low radial volumes (f-PCI 97.0% versus r-PCI 96.6%; P=0.702).
Outcomes
Among all sites performing ≥1 r-PCI before propensity matching, estimated rates of blood transfusion among patients undergoing r-PCI were lower compared with f-PCI at 3 days (0.8% versus 1.6%; event rate difference [ERD], 0.9; 95% confidence interval [CI], 0.4-1.4; P=0.001) and at 7 days (1.2% versus 2.1%; ERD, 0.9; 95% CI, 0.3-1.5; P=0.006, respectively). Among the same group, there was no difference in estimated rates of mortality among patients undergoing r-PCI compared with f-PCI at 30 days (1.2% versus 1.6%; ERD, 0.3; 95% CI, −0.3 to 1.0; P=0.294) or at 360 days (5.7% versus 6.4%; ERD, 0.8; 95% CI, −0.6 to 2.1; P=0.261). Tables 4, 5 , and 6 display Kaplan-Meier estimates at time points of interest for the primary outcomes among propensitymatched patients at sites with ≥1 r-PCI, high and low radial volumes. The estimated rates of blood transfusion did not differ significantly by access site among propensity-matched patients at sites performing ≥1 r-PCI at 3 and 7 days after PCI (Table 4 ). When evaluating rates of transfusion among sites with high radial volumes, the rate of blood transfusions was significantly lower among radial access patients compared with femoral access at 3 days (r-PCI 0.2% versus f-PCI 1.7%; ERD, 1.5; 95% CI, 0.7-2.4; P<0.001) and at 7 days (r-PCI 0.5% versus f-PCI 2.2%; ERD, 1.7; 95% CI, 0.7-2.8; P=0.001; Table 5 ). Among low radial volume sites, there was no significant difference in rates of blood transfusion at 3 or 7 days ( Table 6 ). The estimated rates of mortality did not differ significantly among any of the propensity-matched patients at sites performing ≥1 r-PCI, high or low radial volume sites at any time point (Tables 4, 5, and 6).
Figures 4 and 5 display the probability of being transfusion free with r-PCI versus f-PCI among propensity-matched patients at high and low r-PCI volume sites. The probability of being transfusion free was significantly higher among r-PCI patients at high r-PCI volume sites (P=0.02). Figures 6 and 7 display the probability of survival among propensity-matched patients at high and low r-PCI volume sites; there was no significant difference in survival between r-PCI and f-PCI in both cohorts. Figure 8 shows the association between access site and the outcomes of blood transfusion and mortality among propensity-matched patients at sites with ≥1 r-PCI and at high and low r-PCI volume sites. The risk of blood transfusion was significantly lower among r-PCI patients at high r-PCI volume sites (hazard ratio, 0.4; 95% CI, 0.3-0.7; P<0.001), but it did not differ significantly by access site among patients at sites with ≥1 r-PCI (hazard ratio, 0.8; 95% CI, 0.5-1.4; P=0.522) or among low r-PCI volume sites (hazard ratio, 1.2; 95% CI, 0.6-2.3; P=0.592). The risk of mortality did not differ significantly by access site in any of the cohorts studied.
Discussion
This study shows several key findings related to transradial PCI in the VA: (1) there was a marked increase in the adoption of r-PCI throughout the VA during the study period; (2) the majority of VA catheterization laboratories were low r-PCI volume centers; (3) the advantage of r-PCI compared with f-PCI, in terms of reduced blood transfusion, was limited to sites with higher radial volumes; and (4) there was no significant difference in mortality rates between high and low radial volume centers. These data suggest that routine use of r-PCI and wider application of r-PCI, both of which would likely lead to greater technical proficiency with the procedure, have the potential to improve safety outcomes among veterans undergoing PCI. Studies comparing outcomes between radial and femoral access have come to differing conclusions. Several small studies have shown an association between r-PCI and reduced bleeding; however, when compared directly in a large randomized trial (the Radial Versus Femoral Access for Coronary Intervention [RIVAL] trial), there was no difference in major bleeding, blood transfusion, or mortality at 30 days between radial and femoral access among patients with acute coronary syndrome undergoing coronary angiography or intervention. 4, 25 Subgroup analysis of the RIVAL study population found that reductions in bleeding and mortality were limited to the higher radial access volume sites, suggesting that a radial learning curve must be overcome before the benefits of r-PCI are realized. This hypothesis is further supported by the Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome (RIFLE-STEACS) trial, which compared radial and femoral access in patients with suspected ST-segment-elevation myocardial infarction with participating study interventional cardiologists meeting a volume of >150 PCIs per year and an expertise criterion of ≥50% interventional cases by radial approach per year. In RIFLE-STEACS, compared with patients undergoing femoral access, patients undergoing an r-PCI experienced a significantly less frequent need for blood transfusion and death attributable to cardiac causes. 26 As in RIVAL and RIFLE-STEACS, our data support the findings that the benefits of r-PCI about blood transfusion within the VA are relegated to higher r-PCI volume sites. There was no significant difference in the risk for blood transfusion between radial and femoral access groups within low radial volume sites. Unlike RIVAL and RIFLE-STEACS, the present study did not show a significant mortality benefit among high radial volume centers. There was no statistically significant difference in mortality rates among any of the cohorts. Our study adds to the aforementioned studies about the safety profile of r-PCI by using a large US contemporary registry. It is important to note that despite being large randomized trials, RIVAL included only 122 American patients (1.7% of study population), and RIFLE-STEACS strictly enrolled Italian patients treated at 4 centers with significant r-PCI experience. 4, 26 As demonstrated in previous studies, there was a significant increase in median fluoroscopy time associated with radial access compared with femoral access among propensitymatched patients (23 versus 20 minutes, P<0.001 at all sites with ≥1 r-PCI; 24 versus 22 minutes, P<0.001 at high radial volume sites). The increased fluoroscopy times associated with radial access have been attributed to the increased use of fluoroscopy for guidance past technically difficult upper extremity vessels. 27 It is important to note that the majority of radiation for PCI occurs from cine-angiography with only a small amount attributed to fluoroscopy, thus making fluoroscopy time a poor surrogate marker for radiation dose. 28 Currently, the VA CART Program does not routinely capture patient radiation dose.
Limitations to be considered for this study are as follows: First, this study is not a randomized trial. Therefore, unmeasured confounders may exist (both access and nonaccess related). To minimize these effects, we used propensity matching to create cohorts balanced in a large number of clinical variables related to choice of the access site for the procedure. Second, the blood transfusions were administratively reported rather than clinically reported. As such, other clinical bleeding events could have been missed. However, given our findings, capturing these additional events would likely increase the robustness of our results because using blood transfusion as a surrogate marker for bleeding underestimates the occurrence of this event. Third, the use of blood transfusion as a surrogate for bleeding was implemented to identify significant bleeding events. Unfortunately, individual, institutional, and regional variations in transfusion practice may lead to confounding when using blood transfusion as a surrogate marker. Again, propensity matching was implemented to minimize these effects. Fourth, we did not perform an analysis by operator volume, although we did allow for dependence by operator in the survival models. Many interventional cardiologists at VA centers also perform procedures outside the VA, and we did not have access to these non-VA data. Therefore, any operator-level volume analysis within the CART Program would significantly underestimate the number of procedures performed by these operators. Fifth, the cutoff of 50 r-PCIs described in the literature required to achieve outcomes similar to experienced radial operators was based on operator-level data and not institutional data. 16 Further studies are warranted to determine the minimal number of institutional r-PCI procedures required to achieve outcomes similar to high volume r-PCI centers. Sixth, we could not perform an in-depth statistical analysis of low r-PCI volume sites because of inadequate numbers. Finally, the CART Program only captures successful arterial access; therefore, we could not examine both the number of attempts necessary Figure 7 . Survival according to radial or femoral access among low transradial percutaneous coronary intervention volume sites during study period (propensity matched).
Figure 8.
Adjusted association between transradial percutaneous coronary intervention (r-PCI), blood transfusion, and mortality among sites that performed ≥1 r-PCI, high and low r-PCI volume sites. Propensity-matched patients at sites with ≥1 r-PCI sites (n=49 sites): transfemoral procedures (n=3795 patients), transradial procedures (n=1265 patients). Propensity-matched patients at high r-PCI volume sites (n=5 sites), transfemoral procedures (n=1123 patients), transradial procedures (n=609 patients). Propensitymatched patients at low r-PCI volume sites (n=44 sites), transfemoral procedures (n=1323 patients), and transradial procedures (n=441 patients).
to achieve successful access and the rates of access site crossover between radial and femoral procedures.
Conclusions
Evaluation of a contemporary multicenter registry of PCI procedures performed in the VA demonstrates that use of radial access for PCI has increased over time, but still accounts for the minority of procedures performed. There is wide variation in use of r-PCI across hospitals even within the integrated VA. The association between r-PCI and a comparable efficacy and improved safety profile compared with f-PCI was present among centers with higher radial volumes. These data suggest that increased uptake of r-PCI within the VA which would result in greater r-PCI expertise has the potential to significantly improve the safety of PCI among veterans.
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